The Dietary Supplement EGCG: NOPE(N-Oleyl- Phosphatidyletathanolamine and pigallocatechin-3-Gallato Formula)Helps Patients to Follow a Flexible Dietary Regimen and Induces Loss of Weight in Patients who had Previously Experienced No Response to Other Weight Loss Intervention

Abstract

Background and aims:Obesity is increasing in all countries. The aim of this study was that of evaluating if the treatment with the dietary supplement ( N-oleyl-phstatidylethanolamine and epigallocatechin-3-gallato formula, EGCG-NOPE) could help patients to follow a flexible dietary regimen. Methods:38 patients (20 males, 18 females, BMI 32-41, aged 33-72 years) were enrolled consecutively. These patients were subjects who had experienced no loss of weight during an intervention program consisting of a short training period, aimed at behaviour modification, followed by a dietary program based on rules of diet, without a fixed amount of calories. These patients were instructed to take EGCG-NOPE, two capsules (EGCG 120 mg and NOPE170 mg each capsule) at 1 hour before lunch and dinner, for two months. The study had a crossover design, and after two months EGCG-NOPE was stopped, the patients continuing to follow only the prescribed dietary rules. After a further two months, patients again took EGCG-NOPE for two more months. The primary end-point of the study was weight loss and a decrease in hip circumference, while the secondary end-point involved metabolic parameters: serum glucose, Homeostasis Model Assessment (HOMA) index, serum LDL and HDL cholesterol and triglycerides. Results: After two months of treatment with EGCG-NOPE, the weight loss was 2.42kg+/-0.3 (p<0.001), and the decrease in hip circumferences was 2.0 cm +/- 0.2 (p<0.001).There was also a decrease in serum glucose (0.083 mm/L p<0.001), HOMA index (0.48 p<0.001), serum LDL cholesterol (0.46 mm/L p< 0.01), and serum triglycerides (0.25 mm/L p<0.001). HDL cholesterol increased by 0.20 mm/L (p<0.01). Following the two months without treatment, the weight and hip circumference were steady. After the next two months of treatment, the patients had a further loss of weight (2.10 kg +/-0.4 p < 0.01) and a further decrease in hip circumference (2.0 +/- 0.1 p < 0.001). Conclusions: EGCG-NOPE, at these doses, has shown that it is capable of decreasing the body weight and hip circumferences in patients who had failed to lose weight during a previous dietary regimen. The improvement in the metabolic parameters during treatment with EGCG-NOPE represents a further aspect of paramount importa